Continuing to Accumulate Peregrine Pharma at Current Levels 7 comments
October 08, 2009
| about: PPHM
Submit
an article to
an article to
-
Font Size:
-
Print
- TweetThis
On Monday Peregrine Pharmaceuticals issued a press release announcing Positive Results From the company's Phase II Bavituximab Lung Cancer Trial. A full copy of the press release is here. The PR had little, if any, influence on the stock price.
I started accumulating shares of this company earlier this year based on the potential of Peregrine's two leading clinical products - Cotara and Bavituximab - which are currently being investigated for effectiveness in Phase II trials to treat various cancer and infectious disease indications.
I'll continue to accumulate for the long term as long as the stock is trading below seventy cents.
Disclosure: Long PPHM
Related Articles
|
-
The Seeking Alpha 100
See allThe top 100 stock
market authors
selected for publication
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most active
Instabloggers.-
1
David Fry
-
2
TraderMark
-
3
Don Dion
-
4
Cliff Wachtel
-
5
Mike Havrilla
Top Instabloggers » -
1
-
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
And here is plug for Cotara from no less than Genentech. though I'm not sure how the patent will be enforced on this.
1: Handb Exp Pharmacol. 2008;(181):291-328.
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
L. A. Khawli (3, 4), P. Hu (3) and A. L. Epstein (5)
(3) Department of Pathology, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA
(4) Genentech, Inc., One DNA Way, South San Francisco, CA 94080, USA
(5) Department of Pathology, USC Keck School of Medicine, 2011 Zonal Avenue, HMR 205, Los Angeles, CA 90033, USA
This chapter describes the generation of novel reagents for the treatment of cancer using fusion proteins constructed with natural ligands of the immune system. Immunotherapy is a powerful therapeutic modality that has not been fully harnessed for the treatment of cancer. We and others have hypothesized that if the proper immunoregulatory ligands can be targeted to the tumor, an effective immune response can be mounted to treat both established primary tumors and distant metastatic lesions. Though it is generally believed that immunotherapy has the potential to treat only residual disease, we offer evidence that this approach can, by itself, destroy large tumor masses and produce lasting remissions of experimental solid tumors. From these studies, three major classes of immune activators, namely, cytokines, chemokines, and costimulatory molecules, have been shown to generate antitumor responses in animal models. In addition, the reversal of immune tolerance by the deletion of T regulatory (Treg) cells has been shown to be equally important for effective immunotherapy. In an attempt to identify reagents that can provide an enhanced immune stimulation and treatment of cancer, our laboratory has developed a novel monoclonal antibody targeting approach, designated Tumor Necrosis Therapy (TNT), which utilizes stable intracellular antigens present in all cell types but which are only accessible in dead and/or dying cells. Since tumors contain necrotic and degenerating regions that account for 30–80% of the tumor mass, this targeting approach can be used to deliver therapeutic reagents to the core of tumors, a site abundant in tumor antigens. In our first set of reagents, a panel of cytokine fusion proteins was genetically engineered using monoclonal antibody chimeric TNT-3 (chTNT-3) directed against necrotic regions of tumors (single-stranded DNA) fused with IL-2, or GM-CSF, or TNFαa, or IFNγ. Tested against different solid tumors, these reagentswere found to mount an effective although transient immune response to tumor especially when used in combination.